AI IN MEDICAL IMAGING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In March 2024, Philips and SyntheticMR partnered to launch an AI-based quantitative brain imaging system, enhancing the diagnosis of neurological disorders such as multiple sclerosis, traumatic brain injuries, and dementia. The new software suite, Smart Quant Neuro 3D MRI, combines Philips' SmartSpeed image-reconstruction technology, the 3D SyntAc clinical application, and SyntheticMR’s SyMRI NEURO 3D tissue assessment software.
• In January 2024, GE HealthCare announced an agreement to acquire MIM Software, a U.S.-based global provider of medical imaging analysis and AI solutions in fields such as molecular radiotherapy, radiation oncology, urology, and diagnostic imaging. This acquisition aims to integrate MIM Software's imaging analytics and digital workflow capabilities across various care areas, enhancing innovation and differentiating GE HealthCare's solutions to positively impact patients and healthcare systems worldwide.
• In November 2023, GE HealthCare unveiled its AI suite, MyBreastAI, at the RSNA 2023 conference. This advanced product is designed to streamline radiologists' workflows by providing sophisticated tools to detect and diagnose breast cancer at earlier stages, ultimately improving patient outcomes.
• In November 2023, Canon Medical Systems introduced two of its four new computed tomography scanners, which utilize the enhanced Aquilion CT platform and incorporate artificial intelligence algorithms to improve image quality and simplify scanner workflows
• In September 2023, COTA, a company specializing in real-world oncology data and analytics, launched Vista, an extensive automated EHR dataset designed to accelerate cancer research and implement reliable generative artificial intelligence in cancer care. Vista leverages automated data abstraction, machine learning algorithms, and medical expert oversight to extract clinically relevant information from electronic medical records, providing biopharmaceutical companies with timely insights to expedite the development of life-saving therapies.